| Today’s Big NewsApr 2, 2024 |
| By Angus Liu Lonza’s search for a CEO has led the Swiss CDMO giant to its compatriot competitor, Siegfried. The appointment of Wolfgang Wienand could end a period of leadership instability marked by multiple CEO handovers since 2019. |
|
|
|
By Gabrielle Masson More than 60 years after RhoGAM’s approval, Johnson & Johnson's Katie Abouzahr, M.D., is hoping to build off the pharma’s own legacy and bring another maternal fetal immunology treatment to market. |
By Conor Hale 3M has finished carving out its healthcare business, formally establishing Solventum as an independent, St. Paul, Minnesota-based manufacturer of a medtech catalog that brought in $8.2 billion in 2023 sales. |
By Kevin Dunleavy Another sign that the post-pandemic reshaping of the CDMO industry isn't over came Tuesday as one of the sector’s most powerful companies, Recipharm, sold off seven of its manufacturing and development facilities. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now!
|
|
By Max Bayer Verve has halted enrollment in a phase 1 study testing its lead asset after a patient experienced two sets of grade 3 side effects. The focus now is on a second PCSK9 base editor, VERVE-102. |
By Conor Hale TriClip reinforces the valve separating the heart’s right atrium and ventricle by grasping together its flaps and forming a tighter seal. |
By Andrea Park AbbVie likes big bets, and it cannot lie. In its latest corporate marketing campaign, the Big Pharma is pulling back the curtain to show off the work that goes into its drug development. |
By Nick Paul Taylor Gritstone bio’s gamble on a novel endpoint has backfired. The cancer vaccine failed to trigger hoped-for changes in circulating tumor DNA, causing the phase 2 trial to miss its primary endpoint and leaving the biotech clinging to immature survival data. |
By Angus Liu After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market. |
By Conor Hale Developed in collaboration with the Mayo Clinic, the software can detect a key indicator of heart performance through Eko's digitally enhanced stethoscopes. |
By Nick Paul Taylor The American Liver Foundation is rolling out new patient resources, programs and support to mark Donate Life Month, an annual event focused on the importance of organ, eye and tissue donation. |
By Max Bayer Roivant's brepocitinib is back in the driver's seat with new phase 2 NIU data that the company is touting as some of the best seen in the indication. The asset is rebounding from a midstage lupus failure at the end of 2023. |
By Zoey Becker Merz Therapeutics, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug Amprya ahead of a court auction. |
By Andrea Park After nearly two decades spent working with the World Health Organization to supply billions of praziquantel tablets to help treat schistosomiasis, Merck KGaA has recently tacked on an additional awareness-raising component to its efforts to eliminate the parasitic disease also known as bilharzia. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now.
|
|
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
